Effects of Laparoscopic Sleeve  Gastrectomy on Central Obesity and  Metabolic Syndrome in Indian Adults- A  Prospective Study

Sethi, Pulkit; Thillai, Manoj; Nain, Prabhdeep Singh; Ahuja, Ashish; Vayoth, Sudheer Othiyil; Khurana, Preetika

doi:10.7860/jcdr/2017/24477.9232

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gill et al examined the effect of SG on participants with T2D, reporting after a mean follow-up of 13.1 months, with 26.9% showing improvements in glycaemic control, and a mean reduction of −1.7% (−18.0 mmol/mol) in A1C [24,25]. The beneficial effects of SG on glucose homeostasis were also reported in improvements of A1C across multiple studies 6 months postoperatively, with reductions in A1C by 2.5% [26] and 1.6% [27]. However, a comparable A1C reduction of 1.6% was seen in a cohort with T2D and a substantially lower baseline BMI of 27.7 kg/m 2 [28], indicating diabetes remission is weight independent.…”

Section: Discussionmentioning

confidence: 99%

Temporal Effects of Sleeve Gastrectomy on Glucose-Insulin Homeostasis and Incretin Hormone Response at 1 and 6 Months

et al. 2020

View full text Add to dashboard Cite

Background Bariatric surgery is an effective treatment for morbid obesity and glycaemic dysfunction. Objectives The aim of the work was to examine both the static and dynamic changes of glucose-insulin homeostasis and incretin hormone response following sleeve gastrectomy (SG) in a sample of 55 participants preoperatively and 1 month and 6 months postoperatively. The focus was on a sample of patients with impaired glucose tolerance and type 2 diabetes (T2D). Setting Morriston Hospital, UK. Methods Prospective study comprising of 55 participants with impaired glucose homeostasis and T2D undergoing SG (mean body mass index [BMI] 50.4 kg/m 2 , mean glycated haemoglobin [A1C] 7.4%). Serial measurements of glucose, insulin, Cpeptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) were performed during oral glucose tolerance testing preoperatively and 1 and 6 months postoperatively. Areas under the curve (AUC) were examined at 30, 60, and 120 min. Results We observed significant improvements in measures of obesity, as well as static and dynamic measures of glucose, insulin, C-peptide and HOMA. Furthermore, significant increases in GLP-1 response as early as 6 months postoperatively were also seen. Conclusions To our knowledge, no study has examined the detailed dynamic changes in glucose and insulin homeostasis in this number of participants undergoing SG in relation to incretin hormones GIP and GLP-1. This current study supports the role of SG for the treatment of obesity-related glucose dysregulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Temporal Effects of Sleeve Gastrectomy on Glucose-Insulin Homeostasis and Incretin Hormone Response at 1 and 6 Months

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In case of obese and extremely obese (BMI > 50) patients it allows for the reduction of body weight with simultaneously few perioperative complications. As a singular surgical procedure, it helps regain control over the parameters of dyslipidaemia and metabolic syndrome and also leads to significant improvement in glucose level, and even to remission of diabetes in most of the population [31]. Based on that it could be assumed that majority of examined men were qualified for SG because they were characterised by significantly higher body weight (149.64 kg) and longer waist circumference (144.31 cm) that patients qualified for RYGB (body mass -140.3 kg; waist circumference -141.62 cm).…”

Section: Discussionmentioning

confidence: 99%

Profiles of patients qualified for bariatric surgeries with Roux-en-Y gastric bypass and sleeve gastrectomy methods

Komorniak¹,

Hoffmann²,

Kowalewski³

et al. 2020

jhi

View full text Add to dashboard Cite

Introduction: Bariatric surgery is one of the methods of extreme obesity treatment used in case of patients with body mass index (BMI) ≥ 40 kg/m 2 or BMI ≥ 35 kg/m 2 and accompanying diseases (e.g. hypertension) for whom previous conservative treatment was not successful. Aim of the study: To determine the anthropometric and biochemical profiles of patients qualified for Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Material and methods: The study involved 60 patients qualified for surgical treatment. The standardized Food Frequency Questionnaire supplemented by a survey which contained questions on previous attempts to lose weight and their results (including yo-yo effect) were administered. The anthropometric measurements included weight, height, waist and hip circumference. Biochemical analysis of blood (lipid profile, liver profile, glucose, glycated haemoglobin and C-reactive protein) were performed using calorimetric method. All the results were statistically analysed using the STATISTICA 12 software. Results: The patients had a history of numerous attempts (≥ 6) to lose weight using unbalanced diets. Women qualified for SG had higher levels of parameters indicating the presence of inflammatory state, dyslipidaemia and improper glycaemia. Men qualified for RYGB had significantly higher values of γ-glutamyl transpeptidase. Conclusions: Numerous unsuccessful attempts to lose weight can signify a low level of nutritional knowledge and the need to educate the patients both before and after the surgery. Patients at higher perioperative risk (due to anthropometric and biochemical parameters) were qualified to less invasive surgery treatment. Higher risk of developing cholelithiasis after the surgery would be attributed to irrational attempts of body weight loss before the procedure, and not to the RYGB itself.

show abstract

“…LAGB placement may be technically easier than the other bariatric operations, but it has been associated with a higher reoperation rate[ 15 ] with approximately 20% of the patients requiring a reoperation at 4.5 years postoperatively[ 72 , 75 ]. In addition, although LAGB placement can achieve a significant loss of weight, the results are inferior to those seen with either SG[ 35 ] or RYGB[ 50 ]. Other aspects of MS are less improved, and these findings are to a certain extent attributed to the unchanged postoperative plasma ghrelin levels[ 40 ].…”

Section: Surgical Managementmentioning

confidence: 99%

Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!

Ziogas

Zapsalis

Giannis

et al. 2020

WJH

View full text Add to dashboard Cite

Metabolic syndrome (MS) is defined as the constellation of obesity, insulin resistance, high serum triglycerides, low high-density lipoprotein cholesterol, and high blood pressure. It increasingly affects more and more people and progressively evolves into a serious issue with widespread healthcare, cost, and quality of life associated consequences. MS is associated with increased morbidity and mortality due to cardiovascular or chronic liver disease. Conservative treatment, which includes diet, exercise, and antidiabetic agents, is the mainstay of treatment, but depends on patient compliance to medical treatment and adherence to lifestyle modification recommendations. Bariatric surgery has recently emerged as an appropriate alternative treatment with promising long-term results. Sleeve gastrectomy and Roux-en-Y gastric bypass constitute the most commonly performed procedures and have been proven both cost-effective and safe with low complication rates. Liver transplantation is the only definitive treatment for end-stage liver disease and its utilization in patients with non-alcoholic steatohepatitis has increased more than fivefold over the past 15 years. In this review, we summarize current state of evidence on the surgical treatment of MS.

show abstract

Effects of Laparoscopic Sleeve Gastrectomy on Central Obesity and Metabolic Syndrome in Indian Adults- A Prospective Study

Cited by 4 publications

References 24 publications

Temporal Effects of Sleeve Gastrectomy on Glucose-Insulin Homeostasis and Incretin Hormone Response at 1 and 6 Months

Temporal Effects of Sleeve Gastrectomy on Glucose-Insulin Homeostasis and Incretin Hormone Response at 1 and 6 Months

Profiles of patients qualified for bariatric surgeries with Roux-en-Y gastric bypass and sleeve gastrectomy methods

Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!

Contact Info

Product

Resources

About